Your blood can reveal your risk for heart disease

However, the use of risk prediction calculators has declined in the primary care setting because the currently available calculators only explain a modest proportion of the incidence. For myocardial infarction, it is estimated that 15-20% of the patients had none of the traditional risk factors and would be classified as "low risk."

"Our study showed that by measuring a combination of five different microRNAs and adding this information to the traditional risk factors for cardiovascular disease, we could identify those that were going to experience a myocardial infarction with considerably improved precision," says Anja Bye, first author of a study recently published in Journal of Molecular and Cellular Cardiology and researcher at K. G. Jebsen -- Center for Exercise in Medisine (CERG) at the Norwegian University of Science and Technology (NTNU). Colleagues at the University of Oslo and the Dept. of Public Health and General Practice (NTNU) have been important collaborators for this study.

There have been several attempts during the last years to improve the risk prediction calculators by adding new bio markers. Some calculators add information of an inflammation marker in blood called CRP (C-reactive protein) or a diabetic marker called HbA1c (glycosylated hemoglobin). This increases the accuracy of the calculators, but still there is a need for new cardiovascular bio markers that could complement the assessment of traditional risk factors, to identify the individuals at risk with greater precision than today.

It was based on this that the researchers designed this study to explore the possibility of a new type of bio marker called circulating microRNAs, to predict 10-year risk for myocardial infarction.

They included 212 healthy participants (40-70 years) from the Nord-Trøndelag Health Study 2 (HUNT2, blood collected in 1996) that either died from myocardial infarction within 10 years or remained healthy at the time of HUNT3 (2006). 179 different microRNAs were quantified in blood samples from these participants.

"For all bio marker studies, replication of the results in new studies is essential to determine the strength of the bio markers, and to evaluate the potential use in a clinical setting. This is why we have initiated a new study, in collaboration with Karolinska Institutet, to further test these microRNAs in new participants from the HUNT study," Bye says. Two medical students from CERG will work on this study during the autumn, and we expect to have the new results ready for publication in January 2017.